RE: Brilliant RNS !18 Dec 2020 07:32
Imagine what a “commercial deal” would do for Vela’s SP in March. This just goes to show how much of a bargain the SP is right now.
“ Unlike many other treatments AZD1656 is not virus specific, as it is activating cells within our own body. This gives the treatment an advantage over many other treatments, and potentially it could be used in other virally induced respiratory diseases including other mutations of coronavirus, MERS and pneumonia. This gives AZD1656 longevity as a treatment beyond the current pandemic. AZD1656 is an orally available tablet that is stable at room temperature, making it suitable for use around the world. Furthermore, should the trial be successful, we expect to agree a commercial deal with a partner almost immediately."